# Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer

> **NCT05681390** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 30 (estimated)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05681390
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05681390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05681390, "Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05681390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*